超低潮气量通气对COVID-19 ARDS患者1年功能结局的影响:一项随机对照试验的长期随访分析
VT4COVID为法国10个ICU开展的多中心、开放标签、随机对照优效性试验,纳入COVID-19 ARDS且PaO2/FiO2≤150 mmHg患者,比较超低潮气量(ULTV,4 mL/kg PBW)与低潮气量(LTV,6 mL/kg PBW)通气。1年时MoCA 5分钟评分在ULTV组显著更低(中位差-2分,95%CI -4-0,p<0.05),SF-36与IES-R无差异;事后分析示MoCA评分与ARDS管理期间PaCO2的AUC或最大值显著相关(p<0.01),与PaO2无关。
要点
- 在COVID-19 ARDS且PaO2/FiO2≤150 mmHg人群中,ULTV(4 mL/kg PBW)与LTV(6 mL/kg PBW)相比,1年死亡率无显著差异(46% vs 42%,HR 1.19,95%CI 0.79-1.80)。
- 1年时ULTV组MoCA 5分钟评分显著低于LTV组(中位差-2分,95%CI -4-0,p<0.05),提示认知功能轻度下降。
- SF-36与IES-R评分两组无显著差异,未发现其他长期功能结局的显著影响。
- 事后分析中MoCA 5分钟评分与ARDS管理期间PaCO2的AUC或最大值显著相关(p<0.01),与PaO2的AUC或最小值无关。
- 该研究为开放标签设计,患者、研究者和结局评估者均未设盲;1年结局评估仅覆盖存活患者中71%可评估者。
适用人群与场景
- 纳入:COVID-19 ARDS患者,PaO2/FiO2≤150 mmHg,来自法国10个ICU,随机接受ULTV(VT 4 mL/kg PBW)或LTV(VT 6 mL/kg PBW)。
- 排除人群:原文未提及。
- 场景:ICU机械通气期间;病情阶段为ARDS急性期。
诊断标准与关键阈值
- ARDS诊断标准原文未提及具体定义;纳入条件为COVID-19 ARDS且PaO2/FiO2≤150 mmHg。
- 干预分组:ULTV组潮气量4 mL/kg预测体重(PBW);LTV组潮气量6 mL/kg PBW。
- 长期结局评估时间点:第365天。
处置流程与药物剂量
- 原文未提及具体通气设置目标(如平台压、PEEP、呼吸频率)或PaCO2允许范围。
- ULTV组目标潮气量为4 mL/kg PBW;LTV组目标潮气量为6 mL/kg PBW;均未提及具体给药途径或疗程细节。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征。
研究设计与关键结果
- 主要终点(1年死亡率,事后添加):ULTV组47/102(46%)vs LTV组44/106(42%),HR 1.19(95%CI 0.79-1.80),无显著差异。
- 1年MoCA 5分钟评分:ULTV组显著低于LTV组,中位差-2分(95%CI -4-0),p<0.05;可评估者分别为39/55(71%)和44/62(71%)。
- SF-36与IES-R评分两组无显著差异。
- 事后分析:MoCA 5分钟评分与ARDS管理期间PaCO2的AUC或最大值显著相关(p<0.01),与PaO2的AUC或最小值无关。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)的长期随访分析。
- 证据等级或推荐强度:原文未提及。
- 局限:开放标签设计,患者、研究者和结局评估者均未设盲;7例失访,34例存活患者至少一项评分数据缺失;1年结局仅71%可评估;1年死亡率为事后添加的结局;事后分析为探索性。
对床旁实践的改变
- 在COVID-19 ARDS且PaO2/FiO2≤150 mmHg患者中,采用ULTV(4 mL/kg PBW)虽未增加1年死亡率,但与1年时认知功能轻度下降相关,决策时需权衡肺保护与潜在认知风险。
- 若临床考虑使用ULTV,应关注PaCO2暴露水平,因事后分析提示PaCO2的AUC或最大值与认知评分下降相关,而PaO2无关。
- 该研究不改变LTV(6 mL/kg PBW)作为对照策略的可行性;原文未提及其他ARDS人群或非COVID-19 ARDS的适用性。
- 常见陷阱:不能将1年MoCA中位差-2分直接等同于临床痴呆诊断;该差异的临床最小重要差异原文未提及。
指南或共识出处
- 原文未提及指南或共识名称;试验注册于ClinicalTrials.gov(NCT04349618)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ultra-low tidal volume ventilation (ULTV) aims to minimize ventilator-induced lung injury in acute respiratory distress syndrome (ARDS), but is associated with an increase in arterial carbon dioxide (PaCO2). This follow-up study aimed to evaluate whether ULTV impacted long-term pre-specified secondary outcomes in the VT4COVID trial.
METHODS: VT4COVID was an open-label multicenter randomized controlled superiority trial performed in ten French intensive care units. Eligible patients were COVID-19 ARDS patients with arterial oxygen pressure (PaO2) over inspired oxygen fraction (FiO2) ≤ 150 mmHg, randomized to ULTV with tidal volume (VT) 4 mL.kg- 1 predicted body weight (PBW), or low VT ventilation (LTV) with VT 6 mL.kg- 1 PBW. Participants, investigators, and outcome assessors were unblinded to group assignment. The following prespecified secondary outcomes were assessed at day-365: MoCA 5-minute, SF-36 and IES-R scores; mortality at day-365 was added a posteriori as an outcome. Scores were compared between arms with the Mann-Whitney test, and mortality was compared between groups with a Cox proportional-hazard model. All analyses (except mortality at day-365) were conducted according to a modified intention-to-treat principle.
RESULTS: Two hundred and fifteen patients were randomized to ULTV (n = 106) or LTV (n = 109) between April,2020 and April,2021. Seven patients were lost to follow-up and 34 surviving patients had missing data for at least one score. Mortality at day-365 was not significantly different between ULTV and LTV arms (47/102 [46%] vs. 44/106 [42%], hazard ratio 1.19 (95% confidence interval (CI95%):0.79-1.80)). The other secondary outcomes were evaluated in 39/55 [71%] and 44/62 [71%] patients in the ULTV and LTV arm, respectively. The MoCA 5-minute score was significantly lower in the ULTV arm (median difference: -2 [CI95%:-4-0] points, p < 0.05). There was no significant difference in SF-36 and IES-R scores between groups. In a post-hoc analysis, MoCA 5-minute score was significantly associated with area under curve (AUC) or maximal PaCO2 during ARDS management (p < 0.01), but not with AUC or minimal PaO2.
CONCLUSIONS: ULTV is associated with a small but significant decrease in cognitive status at day-365 possibly related to exposure to higher PaCO2.
TRIAL REGISTRATION: The trial was prospectively registered with ClinicalTrials.gov (NCT04349618) on April 16, 2020.
参考来源
- Richard JC, Chorfa F, Terzi N, et al. Impact of ultra-low tidal volume ventilation on 1-year functional outcome in COVID-19 ARDS patients. A long-term follow-up analysis of a randomized controlled trial. Crit Care. 2026. PMID: 42449426. doi:10.1186/s13054-026-06195-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。